The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Strategies to Optimize Adult Stem Cell Therapy for Tissue Regeneration
Open accessAbstract
Stem cell therapy aims to replace damaged or aged cells with healthy functioning cells in congenital defects, tissue injuries, autoimmune disorders, and neurogenic degenerative diseases. Among various types of stem cells, adult stem cells (i.e., tissue-specific stem cells) commit to becoming the functional cells from their tissue of origin. These cells are the most commonly used in cell-based therapy since they do not confer risk of teratomas, do not require fetal stem cell maneuvers and thus are free of ethical concerns, and they confer low immunogenicity (even if allogenous). The goal of this review is to summarize the current state of the art and advances in using stem cell therapy for tissue repair in solid organs. Here we address key factors in cell preparation, such as the source of adult stem cells, optimal cell types for implantation (universal mesenchymal stem cells vs. tissue-specific stem cells, or induced vs. non-induced stem cells), early or late passages of stem cells, stem cells with endogenous or exogenous growth factors, preconditioning of stem cells (hypoxia, growth factors, or conditioned medium), using various controlled release systems to deliver growth factors with hydrogels or microspheres to provide apposite interactions of stem cells and their niche. We also review several approaches of cell delivery that affect the outcomes of cell therapy, including the appropriate routes of cell administration (systemic, intravenous, or intraperitoneal vs. local administration), timing for cell therapy (immediate vs. a few days after injury), single injection of a large number of cells vs. multiple smaller injections, a single site for injection vs. multiple sites and use of rodents vs. larger animal models. Future directions of stem cell-based therapies are also discussed to guide potential clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A perivascular origin for mesenchymal stem cells in multiple human organs
Crisan, M., Yap, S., Casteilla, L., Chen, C.-W., Corselli, M., Park, T. S., Andriolo, G., Sun, B., Zheng, B., Zhang, L., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.07.003 · Cited by 3,991 · cited 1×
“Recently, more evidences have indicated that MSCs exist nearly in any vascularized tissues in vivo [16].”
BackgroundA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“One of the effective and controllable methods to apply growth factors that can augment stem cell treatments is genetic manipulation of the cells overexpressing diverse growth factors before implantation [57,58].”
Mesenchymal Stem Cell Homing: The Devil Is in the Details
Karp, J. M., & Leng Teo, G. S. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.02.001 · Cited by 1,445
Virus treatment questioned after gene therapy death
Lehrman, S. (1999) · Nature · doi:10.1038/43977 · Cited by 576 · cited 1×
“One of the effective and controllable methods to apply growth factors that can augment stem cell treatments is genetic manipulation of the cells overexpressing diverse growth factors before implantation [57,58].”
Pan, C., Kumar, C., Bohl, S., Klingmueller, U., & Mann, M. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800258-mcp200 · Cited by 561 · cited 1×
“In addition, cell lines usually lose their initial cell morphology and differentiation capacity with increasing passages, causing weak regeneration capability after cells are implanted in vivo [47] and abnormal alterations of cell DNA, RNA, and proteins over time during long-term culture [48].”
BackgroundNiu, X., Feng, Q., Wang, M., Guo, X., & Zheng, Q. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.11.020 · Cited by 296
Boyette, L. B., Creasey, O. A., Guzik, L., Lozito, T., & Tuan, R. S. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2013-0079 · Cited by 121
Gharibi, T., Ahmadi, M., Seyfizadeh, N., Jadidi-Niaragh, F., & Yousefi, M. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.01.002 · Cited by 104
Van Koppen, A., Joles, J. A., Bongartz, L. G., Van Den Brandt, J., Reichardt, H. M., Goldschmeding, R., Nguyen, T. Q., & Verhaar, M. C. (2012) · Cell Transplantation · doi:10.3727/096368912x636795 · Cited by 39
Cited by
Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application
Caplan, H., Olson, S. D., Kumar, A., George, M., Prabhakara, K. S., Wenzel, P., Bedi, S., Toledano-Furman, N. E., Triolo, F., Kamhieh-Milz, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01645 · Cited by 306
Takeuchi, R., Katagiri, W., Endo, S., & Kobayashi, T. (2019) · PLOS ONE · doi:10.1371/journal.pone.0225472 · Cited by 210
Vargas-Rodríguez, P., Cuenca-Martagón, A., Castillo-González, J., Serrano-Martínez, I., Luque, R. M., Delgado, M., & González-Rey, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814117 · Cited by 25
Metadata
- Authors
- Liu, S., Zhou, J., Zhang, X., Liu, Y., Chen, J., Hu, B., Song, J., & Zhang, Y.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2016-06-21
- Volume
- 17
- Issue
- 6
- Pages
- 982
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2464579909
- Cited by
- 174
- References
- 9
- FWCI
- 12.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.